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Background: Complete resection is a standard treatment for patients with Masaoka-Koga stages II and 
III thymoma, however the role of postoperative radiotherapy (PORT) is controversial. We analyzed data 
collected from 4 Korean hospitals to determine the effectiveness of PORT in stage II and III thymoma 
patients.
Methods: Between January 2000 and December 2013, 1,663 patients underwent surgery for thymic tumors 
at the 4 hospitals. Among them, 668 patients (527 with stage II and 141 with stage III) were investigated, 
among whom, 443 received PORT (335 with stage II and 108 with stage III). Propensity score matching 
(PSM) was performed, and 404 patients (346 with stage II and 58 with stage III) were selected. 
Results: Perioperative characteristics were similar in the PORT and non-PORT groups after PSM. On 
survival analysis of stage II patients, the PORT and non-PORT groups showed no difference in either 5-year 
recurrence-free survival (RFS) (96.3% vs. 96.6%, P=0.622) or 5-year overall survival (OS) (94.6% vs. 93.8%, 
P=0.839). However, among stage III patients, the PORT group showed significantly better 5-year RFS (75.7% 
vs. 50.1%, P=0.040) and 5-year OS (86.5% vs. 54.7%, P=0.001). On multivariate Cox regression analysis, 
PORT was a significant positive prognostic factor in terms of both RFS (P=0.005) and OS (P=0.004) in 
patients with stage III thymomas, but not in those with stage II disease (P=0.987 and 0.968, respectively).
Conclusions: PORT improved the RFS and OS in stage III thymoma patients, but showed no survival 
benefit in stage II patients.
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Introduction
Thymomas are rare tumors that originate from thymic 
epithelial cells. While they have a relatively low incidence 
rate (accounting for only 0.2–1.5% of all malignancies) (1), 
thymomas are the most common mediastinal mass in 
adults, comprising 20–30% of all such masses (2). Because 
tumor-node-metastasis (TNM) staging is not useful for 
thymomas, the World Health Organization (WHO) 
histologic subtypes (3) or the Masaoka classification (4) are 
widely used for staging thymic epithelial tumors.
The Masaoka staging system has previously been 
shown to be a good predictor of prognosis and survival in 
patients with thymomas (5,6); moreover, the International 
Thymic Malignancy Interest Group (ITMIG) introduced 
a modified Masaoka system for staging thymoma (Koga 
et al.) (7). The treatment of thymomas may involve surgical 
resection, chemotherapy, radiation therapy (RT), or 
combined therapies that are determined by disease stage. 
Of the multimodal therapies available, complete surgical 
resection remains the mainstay of treatment for thymomas 
(5,6). RT has also been used as an adjuvant or palliative 
treatment since thymomas are radiosensitive (8); however, 
the effectiveness of postoperative radiotherapy (PORT) 
remains unclear. According to the ITMIG definitions and 
reporting guidelines for thymic malignancies (9), PORT 
is not indicated following complete resection of a well-
encapsulated thymoma but should be considered in rare 
cases in which a noninvasive thymoma is not completely 
resected or when a patient is a poor surgical risk. In this 
study, we researched the database of the Korean Association 
for Research on the Thymus (KART) to determine the 
efficacy of PORT in patients with thymomas, especially 
those with Masaoka-Koga (M-K) stages II and III disease.
We present the following article in accordance with the 
STROBE reporting checklist (available at http://dx.doi.
org/10.21037/jtd-20-1713).
Methods
Data sources and patient selection
The KART is a research organization established for the 
development and understanding of thymic epithelial tumors. 
The database comprises the electronic medical records of 
1,663 patients collected from 4 Korean institutions between 
January 2000 and December 2013. For our study, patients 
who had benign diseases, M-K stage I and IV thymomas, 
thymic carcinomas, or neuroendocrine carcinomas were 
excluded, as were patients with missing data. Propensity 
score matching (PSM; 1:1) was performed to adjust for age, 
sex, myasthenia gravis, adjuvant chemotherapy, extent of 
surgery, postoperative complications, M-K stage, WHO 
subtypes, pathologic tumor size, complete resection, and 
postoperative chemotherapy (POCT). The WHO subtypes 
were divided into 2 groups based on prognostic relevance 
and statistical effectiveness: patients with A, AB, and B1 
subtypes and those with B2 and B3 subtypes. After PSM, 
the PORT and non-PORT groups each comprised 202 
patients. Both groups were analyzed retrospectively. The 
study was conducted in accordance with the Declaration of 
Helsinki (as revised in 2013). The study was approved by 
institutional review board (No. 4-2020-0861) and informed 
consent was taken from all individual participants.
Definitions
In this study, overall survival (OS) was defined as the length 
of time from the date of the surgical resection to the last 
follow-up date. And, recurrence-free survival (RFS) was 
defined as the time from the surgery to the last follow-up 
date without recurrence.
Statistical analysis
The baseline characteristics of each group were analyzed 
using the independent t-test for continuous variables 
and the chi-square and Fisher’s exact test for categorical 
variables. The paired t-test and McNemar’s test were used 
for continuous and categorical variables, respectively, after 
performing PSM to adjust for confounding variables. 
Continuous data are expressed as means with standard 
deviations or as medians and ranges, whereas categorical 
variables are shown as counts and percentages. OS and 
recurrence-free survival were calculated from the date 
of resection and were estimated using the Kaplan-Meier 
method; differences were evaluated using the log-rank 
test. The Cox proportional hazards model was used to 
evaluate the influence of PORT and other risk factors on 
RFS and OS. Clinicopathological factors were identified 
using univariable analysis, and all factors with P values <0.2 
were subjected to multivariable Cox regression analyses. 
Results are expressed as hazard ratios (HRs) and their 
corresponding 95% confidence intervals. All P values were 
2-sided, and a P value <0.05 was considered significant. All 
statistical analysis was performed using SPSS 23.0 (IBM, 
Armonk, NY, USA).
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Results
Baseline characteristics
Figure 1 shows the patient selection scheme. Of the 668 
patients who met our inclusion criteria (527 with stage II 
and 141 with stage III thymomas), 443 (66.3%) underwent 
PORT (of whom 335 had stage II and 108 had stage III 
disease). The median ages in the non-PORT and PORT 
groups were 53.0 and 50.0 years, respectively, representing a 
significant difference (P=0.031). Myasthenia gravis was more 
common in the PORT group (30.7% vs. 21.3%, P=0.013); 
the A/AB/B1 subtypes were more commonly found in 
the non-PORT group (61.3% vs. 32.1%), while B2/B3 
subtypes were more frequent in the PORT group (67.9% 
vs. 38.7%; P<0.001). Patients with M-K stage II were more 
common than those with stage III in both groups; however, 
the proportion of stage II patients was higher in the non-
PORT group (85.3% vs. 75.6%, P=0.005). There were no 
differences between the groups in term of sex, adjuvant 
chemotherapy, extent of surgical resection, pathologically 
confirmed tumor size, rate of complete resection, and 
postoperative POCT (Table 1).
Following PSM, 404 patients were selected including 346 
with stage II and 58 with stage III (Table 1); the matched 
groups were well-balanced. There were no significantly 
different factors between the non-PORT and PORT 
groups, including among those that were significantly 
different pre-PSM (i.e., myasthenia gravis, WHO subtypes, 
and M-K stage). The median age was 51.5 years in the non-
PORT group and 50.0 years in the PORT group (P=0.420). 
Subgroup analysis according to M-K stage revealed 
that 172 stage II patients and 30 stage III patients received 
PORT; none of the investigated factors were significantly 
different between the non-PORT and PORT groups among 
patients with either disease stage.
RFS and OS
The 5-year RFS rates were not significantly different 
between the non-PORT and PORT patients overall (91.1% 
vs. 93.0%, P=0.373), or between those with stage II disease 
(96.6% vs. 96.3%, P=0.622). However, among stage III 
patients, the 5-year RFS rate was significantly better in the 
PORT group than in the non-port group (75.7% vs. 50.1%, 
P=0.040) (Figure 2). 
Furthermore, OS was significantly longer in stage III 
patients receiving PORT (Figure 2). The 5- and 10-year 
OS rates were both 86.5% in the PORT group, but were 
54.7% and 30.4% in the non-PORT group, respectively 
(P=0.001). However, there was no significant differences 
among stage II patients, where the 5- and 10-year OS rates 
were 94.6% and 84.3% in the PORT group, and 93.8% 
and 87.5% in the non-PORT group, respectively (P=0.839). 
Among all patients, the OS of those receiving PORT was 
not superior to that of patients in the non-PORT group. 
The 5- and 10-year OS rates were 93.1% and 85.1% in the 
PORT group, and 87.5% and 77.9% in the non-PORT 
group, respectively (P=0.160). Among stage III thymoma, 
three patients without PORT died within the postoperative 
1 year. The cause of deaths were 1 myocardial infarction, 1 
thymoma related death, and 1 unknown cause.
Multivariate analysis of RFS 
On univariate analysis of all patients (Table 2), poorer 
RFS was associated with neoadjuvant chemotherapy, B2/




• 443 PORT and 225 non-PORT 
• 527 stage II and 141 stage III thymoma
Final: 404 patients
• 202 PORT and 202 non-PORT 
• 346 stage II and 58 stage III thymoma
Exclusion criteria: 
Thymic carcinoma, neuroendocrine tumors, 
Stages I and IV thymoma, patients with missing data
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B3 WHO subtype, M-K stage III, pathologic tumor size, 
and POCT. In contrast, complete resection was associated 
with improved RFS. On multivariate analysis, only WHO 
subtypes B2/B3 (HR, 2.82; 95% confidence interval (CI), 
1.23–6.45; P=0.014) and M-K stage III (HR, 5.22; 95% CI, 
2.48–10.97; P<0.001) showed higher HRs. PORT did not 
produce a significant change in the HR according to either 
univariate or multivariate analysis (HR, 0.57; 95% CI, 0.28–
1.17; P=0.123).
In stage II patients (Table 3), complete resection was 
associated with improved RFS (HR, 0.09; 95% CI, 0.02–
0.43; P=0.002). In contrast, neoadjuvant chemotherapy was 
associated with a higher HR (45.84; 95% CI, 4.01–524.19; 
P=0.002). PORT did not produce a significant different in 
HR among patients with stage II thymoma (HR, 1.01; 95% 
CI, 0.31–3.33; P=0.987).
 In stage III patients (Table 3), only PORT was associated 
with improved RFS on both univariate analysis (HR, 0.35; 
95% CI, 0.12–1.00; P=0.049) and multivariate analysis (HR, 
0.10; 95% CI, 0.02–0.50; P=0.005).
Multivariate analysis of OS
Among all patients, old age (HR, 1.05; 95% CI, 1.02–1.08; 
P=0.001), neoadjuvant chemotherapy (HR, 2.87; 95% CI, 
1.01–8.12; P=0.047), postoperative complications (HR, 4.01; 





PORT (n=443) P value
Non-PORT 
(n=202)
PORT (n=202) P value
Age, years 0.031 0.420
Mean ± SD 52.9±14.1 50.5±11.9 52.0±14.1 51.0±12.0
Median [range] 53.0 [16–84] 50.0 [17–79] 51.5 [16–84] 50.0 [19–79]
Sex, n (%) 0.165 1.000
Male 109 (48.4) 240 (54.2) 97 (48.0) 97 (48.0)
Female 116 (51.6) 203 (45.8) 105 (52.0) 105 (52.0)
MG, n (%) 48 (21.3) 136 (30.7) 0.013 47 (23.3) 56 (27.7) 0.328
Neoadjuvant CT, n (%) 8 (3.6) 16 (3.6) 1.000 5 (2.5) 6 (3.0) 1.000
Total thymectomy, n (%) 152 (67.6) 326 (73.6) 0.104 139 (68.8) 142 (70.3) 0.820
Complication, n (%) 29 (12.9) 53 (12.0) 0.803 24 (11.9) 26 (12.9) 0.883
WHO subtype, n (%) <0.001 0.180
A, AB, B1 138 (61.3) 142 (32.1) 121 (59.9) 115 (56.9)
B2, B3 87 (38.7) 301 (67.9) 81 (40.1) 87 (43.1)
M-K stage, n (%) 0.005 0.878
II 192 (85.3) 335 (75.6) 174 (86.1) 172 (85.1)
III 33 (14.7) 108 (24.4) 28 (13.9) 30 (14.9)
Tumor size, cm 0.534 0.835
Mean ± SD 6.1±3.2 6.2±2.8 6.1±3.2 6.1±2.7
Median (range) 5.5 (1.0–20.0) 6.0 (0.8–20.0) 5.5 (1.0–20.0) 5.6 (0.8–16.0)
R0 resection, n (%) 208 (92.4) 397 (89.6) 0.265 187 (92.6) 182 (90.1) 0.487
POCT, n (%) 10 (4.4) 21 (4.7) 1.000 10 (5.0) 10 (5.0) 1.000
PORT, postoperative radiotherapy; SD, standard deviation; MG, myasthenia gravis; CT, chemotherapy; WHO, World Health Organization; 
M-K, Masaoka-Koga; R0 resection, complete resection; POCT, postoperative chemotherapy.
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95% CI, 1.96–8.21; P<0.001), and recurrence (HR, 4.11; 
95% CI, 1.76–9.62; P=0.001) were associated with poor 
OS. In contrast, female sex (HR, 0.47; 95% CI, 0.23–0.97; 
P=0.040) was associated with longer OS (Table 2). There 
was no significant different in OS based on administering 
PORT (HR, 0.68; 95% CI, 0.35–1.33; P=0.259).
In stage II patients (Table 4), older age (HR, 1.06; 95% 
CI, 1.03–1.11; P=0.001), postoperative complications (HR, 
5.48; 95% CI, 2.22–13.52; P<0.001), WHO subtypes B2/B3 
(HR, 3.82; 95% CI, 1.33–10.95; P=0.013), and recurrence 
(HR, 10.43; 95% CI, 3.27–33.32; P<0.001) were associated 
with poorer OS. Female sex was associated with a more 
favorable OS in stage II patients (HR, 0.30; 95% CI, 0.12–
0.77; P=0.013). However, PORT was not associated with 
improved OS (HR, 0.98; 95% CI, 0.40–2.43; P=0.968).
As with RFS, PORT was the only factor that was 
significantly associated with improved OS in patients 
with stage III thymomas (HR, 0.17; 95% CI, 0.05–0.56; 
Figure 2 Kaplan-Meier curves and log-rank P values of recurrence-free and overall survival in the PORT versus non-PORT groups. (A) 
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P=0.004) (Table 4). 
Discussion
The choice of treatment is the most important decision 
physicians make regarding their patients. However, 
thymic epithelial tumors are rare, and the heterogeneity 
of treatment recommendations as well as the variations in 
reported outcomes can cause uncertainty regarding the 
optimal treatment for this disease. PORT is conventionally 
administered to patients with thymomas in clinical practice; 
however, its effectiveness has remained unclear (10-12), 
and there is no established consensus on its indication 
(13,14). M-K stage II and III thymomas are both locally 
invasive but non-metastatic; however, stage II thymoma is 
considered an early-stage tumor that has a low recurrence 
rate, whereas stage III thymoma is an advanced-stage tumor 
with a relatively high rate of recurrence (15). Many studies 
have evaluated the efficacy of PORT for the treatment of 
thymomas; however, their results were inconsistent. Some 
researchers found that the benefit of PORT in patients 
with stage II thymoma is questionable, whereas its efficacy 
in patients with stage III has not yet been established 
(10-12,16-25).
Omasa et al. investigated the effectiveness of PORT in 
1,265 patients with stage II and III thymomas and thymic 
carcinomas using the Japanese Association for Research on 
the Thymus (JART) database; they found that PORT did 
not improve the RFS or OS of patients with stage II or III 
thymomas, but did improve the RFS of patients with stage 
Table 2 Univariate and multivariate analysis of recurrence-free survival and overall survival in all patients (total n=404)
Variables
RFS OS
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age 0.98 (0.95–1.01) 0.163 0.98 (0.95–1.00) 0.105 1.05 (1.02–1.07) 0.001 1.05 (1.02–1.08) 0.001
Sex 0.105 0.228 0.003 0.040
Male Reference Reference Reference Reference
Female 0.56 (0.27–1.13) 0.64 (0.31–1.33) 0.36 (0.18–0.71) 0.47 (0.23–0.97)
MG 1.37 (0.66–2.84) 0.406 1.23 (0.59–2.57) 0.576 0.93 (0.47–1.84) 0.831 1.53 (0.67–3.46) 0.313
Neoadjuvant CT 8.68 (3.28–23.00) <0.001 1.67 (0.57–4.92) 0.355 6.30 (2.43–16.44) <0.001 2.87 (1.01–8.12) 0.047
Total thymectomy 0.45 (0.17–1.15) 0.096 0.54 (0.22–1.32) 0.177 0.80 (0.41–1.59) 0.53 0.65 (0.31–1.35) 0.244
Complication 1.51 (0.62–3.68) 0.360 1.60 (0.66–3.90) 0.297 4.43 (2.31–8.52) <0.001 4.01 (1.96–8.21) <0.001
WHO subtype <0.001 0.014 0.719 0.048
A, AB, B1 Reference Reference Reference Reference
B2, B3 4.20 (1.88–9.36) 2.82 (1.23–6.45) 1.12 (0.60–2.09) 2.28 (1.01–5.18)
M-K stage <0.001 <0.001 <0.001 0.313
II Reference Reference Reference Reference
III 8.24 (4.09–16.61) 5.22 (2.48–10.97) 3.36 (1.77–6.37) 1.56 (0.66–3.66)
Pathologic size 1.12 (1.02–1.23) 0.022 1.01 (0.90–1.13) 0.882 1.04 (0.94–1.15) 0.432 1.05 (0.95–1.17) 0.339
R0 resection 0.27 (0.13–0.59) 0.001 0.45 (0.20 1.00) 0.051 1.00 (0.38–2.60) 0.994 1.68 (0.57–4.96) 0.352
POCT 4.05 (1.75–9.38) 0.001 1.83 (0.77–4.37) 0.174 2.15 (0.89–5.21) 0.089 3.61 (1.26–10.31) 0.017
PORT 0.72 (0.36–1.44) 0.350 0.57 (0.28–1.17) 0.123 0.64 (0.34–1.20) 0.164 0.68 (0.35–1.33) 0.259
Recurrence 3.43 (1.75–6.69) <0.001 4.11 (1.76–9.62) 0.001
HR, hazard ratio; CI, confidence interval; MG, myasthenia gravis; CT, chemotherapy; WHO, World Health Organization; M-K, Masaoka-
Koga; R0 resection, complete resection; POCT, postoperative chemotherapy; PORT, postoperative radiotherapy.
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II and III thymic carcinomas (15). In contrast, Jackson et al. 
used the National Cancer Database in the United States 
to investigate the impact of PORT on 4,056 patients with 
stage II and III thymoma and thymic carcinoma, and found 
PORT to be associated with superior OS after performing 
PSM. Subset analysis revealed longer OS rates in patients 
with stage IIB–III disease as well as in those with positive 
margins (26).
Thymic carcinoma is distinct from thymoma, as the 
former has more aggressive features and is associated with 
a low survival rate (15,23,27). Our study evaluated the 
efficacy of PORT in patients with stages II and III thymoma 
but did not include those with thymic carcinoma. PSM was 
performed to minimize bias caused by possible confounding 
factors, and subgroup analyses according to the M-K stage 
were also performed owing to its being the most important 
prognostic factor (15). While previous studies have 
analyzed the efficacy of PORT in patients with completely 
resected tumors, we included those with both complete and 
incomplete resections as we posited that PORT could be 
beneficial in both situations (28). 
 In Korea, the choice of PORT for thymoma patients is 
dependent on separate institutional guidelines or individual 
physicians. PORT was more commonly administered to 
patients in the KART database (63.6% and 76.6% of stage 
II and stage III patients, respectively) than to those in the 
JART database (23.8% and 45.6% of stage II and stage III 
patients, respectively) (15). However, there was no precise 
indication for postoperative irradiation in the KART 
database, and the reason PORT was selected for each 
patient was unclear since decisions varied by institution 
and individual physician. However, such heterogeneity 
in patients receiving PORT in our study may lower the 
selection bias and further lend credence to the positive 
impact of PORT.
In a study of the ITMIG database, Huang et al. found that 
the median OS of patients with thymoma was 18.9 years, 
which is relatively longer than that in patients with other 
solid tumors (27). Given the long OS, it is important to 
investigate RFS, which may be a more pertinent prognostic 
Table 3 Univariate and multivariate analysis of recurrence-free survival in patients with stages II and III thymoma
Variables
Stage II (n=346) Stage III (n=58)
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age 1.00 (0.96–1.05) 0.893 0.99 (0.94–1.05) 0.742 0.98 (0.95–1.01) 0.163 0.91 (0.86–0.97) 0.001
Sex 0.485 0.135 0.543 0.316
Male Reference Reference Reference Reference
Female 0.70 (0.25–1.92) 0.40 (0.12–1.33) 0.73 (0.27–1.99) 0.53 (0.16–1.82)
MG 0.62 (0.17–2.20) 0.456 0.92 (0.19–4.47) 0.912 1.61 (0.60–4.38) 0.347 0.63 (0.13–3.05) 0.563
Neoadjuvant CT 12.58 (1.62–97.87) 0.016 45.84 (4.01–524.19) 0.002 2.10 (0.67–6.63) 0.206 3.63 (0.59–22.41) 0.164
Total thymectomy 0.22 (0.04–1.19) 0.078 0.28 (0.06–1.28) 0.100 1.48 (0.48–4.54) 0.497 0.75 (0.12–4.80) 0.763
Complication 2.79 (0.29–27.39) 0.378 3.45 (0.38–31.66) 0.274 1.10 (0.38–3.19) 0.866 9.70 (1.55–60.52) 0.015
WHO subtype 0.094 0.976 0.184 0.029
A, AB, B1 Reference Reference Reference Reference
B2, B3 2.42 (0.86–6.81) 1.02 (0.26–3.94) 2.73 (0.62–12.00) 6.76 (1.21–37.70)
Pathologic size 1.14 (0.99–1.32) 0.075 1.25 (1.05–1.49) 0.012 0.94 (0.81–1.10) 0.467 0.89 (0.77–1.03) 0.105
R0 resection 0.27 (0.08–0.98) 0.046 0.09 (0.02–0.43) 0.002 0.79 (0.81–1.10) 0.467 0.13 (0.02–0.74) 0.021
POCT 6.69 (2.07–21.60) 0.001 2.65 (0.49–14.16) 0.256 1.37 (0.28–6.59) 0.699 1.37 (0.33–5.75) 0.664
PORT 0.78 (0.28–2.14) 0.623 1.01 (0.31–3.33) 0.987 0.35 (0.12–1.00) 0.049 0.10 (0.02–0.50) 0.005
HR, hazard ratio; CI, confidence interval; MG, myasthenia gravis; CT, chemotherapy; WHO, World Health Organization; R0 resection, 
complete resection; POCT, postoperative chemotherapy; PORT, postoperative radiotherapy.
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factor. In our study, we investigated both RFS and OS as 
determinants of prognosis in thymoma patients. While 
PORT produced no differences in the RFS and OS rates of 
the patients overall or only in those with stage II thymomas, 
it was found to significantly improve both RFS and OS in 
patients with stage III disease. It was difficult to explain 
why PORT improved the survival of thymoma only in 
stage III. However, stage III thymoma has a greater risk 
than stage II, thus, PORT could be helpful to patients with 
stage III thymoma. Nonetheless, there should be further 
investigation, as this is contested topic. Meanwhile, the 
WHO subtype analysis was not considered in the study 
design. However, additional analysis was performed using 
the same database. PORT had a positive impact on stage III 
and WHO B2/B3 thymoma (P=0.056 for RFS and P=0.002 
for OS; n=41), but not on stage II and WHO B2/B3 
thymoma (P=0.919 for RFS and P=0.228 for OS; n=127). 
However, further evaluation is warranted.
Generally, patients who experienced disease recurrence 
or who underwent PORT visited the hospital more often, 
and had longer follow-up periods than those who did not 
experience recurrences. Therefore, the positive impact of 
PORT could be overestimated, and our results should be 
interpreted with caution. However, our multivariate analysis 
results do support our finding of a favorable impact of 
PORT in patients with stage III thymomas.
There currently is no consensus on whether PORT has 
a positive impact on OS or RFS. In this study, the benefit 
of PORT on OS and RFS in stage III thymoma was shown. 
However, the study group was relatively small. Therefore, 
in conclusion, it appears that PORT could improve the RFS 
and OS in stage III thymoma.
Limitations
This study had some key limitations. First, the KART 
database we used was assembled from multiple institutions 
and was analyzed retrospectively. Second, the data collection 
Table 4 Univariate and multivariate analysis of overall survival in patients with stages II and III thymoma
Variables
Stage II (n=346) Stage III (n=58)
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age 1.06 (1.02–1.09) 0.002 1.06 (1.03–1.11) 0.001 1.03 (0.98–1.07) 0.245 1.05 (1.00–1.10) 0.038
Sex 0.018 0.013 0.227 0.644
Male Reference Reference Reference Reference
Female 0.36 (0.16–0.84) 0.30 (0.12–0.77) 0.49 (0.16–1.55) 0.71 (0.17–2.99)
MG 0.77 (0.31–1.90) 0.568 1.54 (0.55–4.36) 0.412 0.97 (0.34–2.79) 0.953 0.97 (0.15–6.54) 0.977
Neoadjuvant CT 8.26 (1.10–62.20) 0.040 6.77 (0.68–67.66) 0.103 2.63 (0.80–8.62) 0.110 4.07 (0.69–17.16) 0.056
Total thymectomy 0.68 (0.29–1.60) 0.380 0.52 (0.20–1.38) 0.190 1.15 (0.36–3.61) 0.817 0.92 (0.14–6.25) 0.935
Complication 4.75 (2.01–11.23) <0.001 5.48 (2.22–13.52) <0.001 2.13 (0.76–5.99) 0.151 2.12 (0.54–8.32) 0.283
WHO subtype 0.014 0.013 0.504 0.829
A, AB, B1 Reference Reference Reference Reference
B2, B3 4.69 (1.36–16.10) 3.82 (1.33–10.95) 1.67 (0.37–7.50) 1.20 (0.23–6.35)
Pathologic size 1.05 (0.92–1.21) 0.451 1.06 (0.90–1.24) 0.505 0.89 (0.76–1.06) 0.188 0.91 (0.77–1.07) 0.243
R0 resection 2.59 (0.34–19.59) 0.357 5.20 (0.50–53.55) 0.166 1.06 (0.33–3.35) 0.924 0.77 (0.16–3.63) 0.741
POCT 1.50 (0.35–6.50) 0.589 2.18 (0.22–21.32) 0.501 1.48 (0.46–4.69) 0.510 2.32 (0.50–10.79) 0.282
PORT 1.09 (0.49–2.40) 0.839 0.98 (0.40–2.43) 0.968 0.18 (0.06–0.58) 0.004 0.17 (0.05–0.56) 0.004
Recurrence 4.94 (1.95–12.53) 0.001 10.43 (3.27–33.32) <0.001 1.17 (0.42–3.27) 0.771 1.72 (0.48–6.24) 0.407
HR, hazard ratio; CI, confidence interval; MG, myasthenia gravis; CT, chemotherapy; WHO, World Health Organization; R0 resection, 
complete resection; POCT, postoperative chemotherapy; PORT, postoperative radiotherapy.
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period spanned longer than a decade, and some older 
records lacked certain information such as the indication 
for neoadjuvant therapy. Third, the KART database is 
not based on a nationwide pool of patients, and patients 
may have been lost to follow-up if they subsequently 
visited other institutions; this may have led to the over- 
or underestimation of the follow-up period. Despite these 
limitations, however, the study has several strengths. It 
comprised a large population of thymoma patients listed in 
a multi-institutional database, which improved the pool’s 
heterogeneity. PSM also adjusted for possible confounding 
factors between groups, which improved the objectivity of 
our results. 
Conclusions
PORT can significantly improve the RFS and OS rates 
of patients with stage III thymoma; however, PORT does 
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